The case for using 5-aminosalicyclates in Crohn's disease: Pro

Inflammatory Bowel Diseases

Volumn 11, Issue 6, 2005, Pages 609-612

  Hanauer, Stephen B ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b ST MARK S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CIPROFLOXACIN; MESALAZINE; METHYLPREDNISOLONE; SALAZOSULFAPYRIDINE;

CONTROLLED DRUG RELEASE; CROHN DISEASE; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HUMAN; PRIORITY JOURNAL; REMISSION; REVIEW; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CROHN DISEASE; HUMANS; MESALAMINE; META-ANALYSIS; SULFASALAZINE; TREATMENT OUTCOME;

EID: 20444466001     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MIB.0000160743.24772.69     Document Type: Review

References (31)

1. Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol. 1995;30:699-706.
2. Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology. 1999;117:49-57.
3. Faubion WA Jr., Loftus EV, Jr., Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255-260.
4. Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut. 1994;35:360-362.
5. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut. 1995;37: 674-678.
6. Kane SV, Schoenfeld P, Sandborn WJ, et al. Systematic review: the effectiveness of budesonide therapy for Crohn's disease. Aliment Pharmacol Ther. 2002;16:1509-1517.
7. Sandborn WJ, Feagan BG. Review article: mild to moderate Crohn's disease-defining the basis for a new treatment algorithm. Aliment Pharmacol Ther. 2003;18:263-277.
8. Anthonisen P, Barany F, Folkenborg O, et al. The clinical effect of salazosulphapyridine (Salazopyrin r) in Crohn's disease. A controlled double-blind study. Scand J Gastroenterol. 1974;9:549-554.
9. Van Hees PA, Van Lier HJ, Van Eiteren PH, et al. Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study. Gut. 1981;22:404-409.
10. Summers RW, Switz DM, Sessions JT, Jr., et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology. 1979;77:847-869.
11. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology. 1984;86:249-266.
12. Ursing B, Aim T, Barany F, et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result. Gastroenterology. 1982;83:550-562.
13. Maier K, Fruhmorgen P, Bode JC, et al. Successful management of chronic inflammatory gut disease with oral 5-aminosalicylic acid. Dtsch Med Wschr. 1985;110:363-368.
14. Maier K, Frick H-J, von Gaisberg U, et al. Clinical efficacy of oral mesalamine in Crohn's disease. Can J Gastroenterol. 1990;4:13-18.
15. Saverymuttu SH, Gupta S, Keshavarzian A, et al. Effect of a slow-release 5′-aminosalicylic acid preparation on disease activity in Crohn's disease. Digestion. 1986;33:89-91.
16. Rasmussen SN, Lauritsen K, Tage-Jensen U, et al. 5-Aminosalicylic acid in the treatment of Crohn's disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa. Scand J Gastroenterol. 1987; 22:877-883.
17. Mahida YR, Jewell DP. Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn's disease. Digestion. 1990;45:88-92.
18. Tremaine WJ, Schroeder KW, Harrison JM, et al. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. J Clin Gastroenterol. 1994;19:278-282.
19. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology. 1993;104:1293-1301.
20. Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol. 2004;2:379-388.
21. Scholmerich J, Jenss H, Hartmann F, et al. Oral 5-aminosalicylic acid versus 6-methylprednisolone in active Crohn's disease. Can J Gastroenterol. 1990;4:446-451.
22. Martin F, Sutherland LR, Beck IT, et al. Oral 5-ASA versus prednisolone in short term treatment of Crohn's disease: A multicentre controlled trial. Can J Gastroenterol. 1990;4:452-457.
23. Gross V, Roth M, Fischback W, et al. Comparison between high dose 5-aminosalicylic acid and 6-methylprednisolone in active Crohn's ileocolitis. A multicenter randomized double-blind study. German 5-ASA Study Group. Z Gastroenterol. 1995;33:581-584.
24. Prantera C, Cottone M, Pallone F, et al. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial. Gastroenterology. 1999;116:521-526.
25. Thomsen OO, Cortot A, Jewell D, et al. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N Engl J Med. 1998;339:370-374.
26. Colombel JF, Lemann M, Cassagnou M, et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol. 1999;94: 674-678.
27. Hanauer SB, Krawitt EL, Robinson M, et al. Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group. Am J Gastroenterol. 1993;88: 1343-1351.
28. Gisbert JP, Gomollon F, Mate J, et al. Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review. Dig Dis Sci. 2002;47:471-488.
29. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347: 417-429.
30. Hanauer SB, Sandborn W. Management of Crohn's disease in adults. Am J Gastroenterol. 2001;96:635-643.
31. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53(Suppl 5):V1-V16.